Your browser doesn't support javascript.
loading
A prospective feasibility study of MammoSite accelerated partial breast irradiation for early breast Cancer.
Geary, Rebecca L; Haddad, Taleen; Barry, Aisling; Zuchora, Anysja; McLaughlin, Ray; Kerin, Michael; Sullivan, Francis J; Martin, Joseph.
Afiliação
  • Geary RL; Department of Radiation Oncology, University Hospital Galway, Galway, Ireland. gearyr@tcd.ie.
  • Haddad T; Department of Radiation Oncology, University Hospital Galway, Galway, Ireland.
  • Barry A; Department of Radiation Oncology, University Hospital Galway, Galway, Ireland.
  • Zuchora A; Department of Radiation Oncology, University Hospital Galway, Galway, Ireland.
  • McLaughlin R; Department of Radiation Oncology, University Hospital Galway, Galway, Ireland.
  • Kerin M; Department of Radiation Oncology, University Hospital Galway, Galway, Ireland.
  • Sullivan FJ; Department of Radiation Oncology, University Hospital Galway, Galway, Ireland.
  • Martin J; Department of Radiation Oncology, University Hospital Galway, Galway, Ireland.
Ir J Med Sci ; 189(4): 1203-1208, 2020 Nov.
Article em En | MEDLINE | ID: mdl-32367398
ABSTRACT

BACKGROUND:

Accelerated partial breast irradiation is a potential alternative to standard whole breast irradiation, following breast-conserving surgery, in the management of breast cancer. The MammoSite applicator-based technique allows for the delivery of a higher dose of radiation to the tumour bed and adjacent area, over a shorter treatment period.

AIMS:

To investigate the long-term feasibility of the MammoSite technique in early stage breast cancer in an Irish cohort.

METHODS:

Sixty-two patients with early stage breast cancer were enrolled in this prospective study between November 2005 and October 2012 at the University Hospital Galway. A single-entry MammoSite applicator was inserted post-operatively. A CT scan was performed to assess the balloon to skin distance, the conformance of target tissue to balloon surface and balloon symmetry. A total dose of 34 Gy was delivered over 10 fractions twice daily.

RESULTS:

Median follow-up was 10 years. 91.9% (57/62) completed the full course of MammoSite treatment. Technical issues with the MammoSite balloon precluded three patients from completing the full course of treatment. On last follow-up, 6.4% (4/62) of patients had developed an ipsilateral breast recurrence. Half of these recurrences occurred more than 10 years after the initial breast cancer treatment. The most common toxicities observed were fibrosis (67.7%), pain (61.3%) and skin erythema (35.5%).

CONCLUSION:

The use of the MammoSite technique, as an alternative to standard whole breast irradiation, is feasible in a typical Irish clinical setting with integrated multidisciplinary team input.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias da Mama Tipo de estudo: Observational_studies Limite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias da Mama Tipo de estudo: Observational_studies Limite: Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article